Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer

PURPOSE: Clinical biomarkers to identify patients unlikely to benefit from CDK4/6 inhibition (CDK4/6i) in combination with endocrine therapy (ET) are lacking. We implemented a comprehensive circulating tumor DNA (ctDNA) analysis to identify genomic features for predicting and monitoring treatment re...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Andrew A., Luo, Jingqin, Zheng, Tiantian, Dai, Chao, Dong, Xiaoxi, Tan, Lu, Suresh, Rama, Ademuyiwa, Foluso O., Rigden, Caron, Rearden, Timothy P., Clifton, Katherine, Weilbaecher, Katherine, Frith, Ashley, Tandra, Pavan K., Summa, Tracy, Haas, Brittney, Thomas, Shana, Hernandez-Aya, Leonel F., Peterson, Lindsay L., Wang, Xiaohong, Luo, Shujun J., Zhou, Kemin, Du, Pan, Jia, Shidong, King, Bonnie L., Krishnamurthy, Jairam, Ma, Cynthia X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150240/
https://www.ncbi.nlm.nih.gov/pubmed/36693175
http://dx.doi.org/10.1158/1078-0432.CCR-22-2177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150240/
https://www.ncbi.nlm.nih.gov/pubmed/36693175
http://dx.doi.org/10.1158/1078-0432.CCR-22-2177

Ejemplares similares